Is ASPARTATE AMINOTRANSFERASE INCREASED a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed ASPARTATE AMINOTRANSFERASE INCREASED.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 179 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported ASPARTATE AMINOTRANSFERASE INCREASED to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and ASPARTATE AMINOTRANSFERASE INCREASED. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause ASPARTATE AMINOTRANSFERASE INCREASED, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes ASPARTATE AMINOTRANSFERASE INCREASED. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if ASPARTATE AMINOTRANSFERASE INCREASED ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing ASPARTATE AMINOTRANSFERASE INCREASED: 179
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where ASPARTATE AMINOTRANSFERASE INCREASED is a reported side effect: 5.3770%

FDA reports of any drug causing ASPARTATE AMINOTRANSFERASE INCREASED : 31671
Average percentage for all medicated patients where ASPARTATE AMINOTRANSFERASE INCREASED is reported as a complication: 0.1985%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with ASPARTATE AMINOTRANSFERASE INCREASED:

ASPIRIN (1980 patients)
TRACLEER (1808 patients)
LIPITOR (1347 patients)
LASIX (1310 patients)
PREDNISOLONE (1261 patients)
CYMBALTA (1231 patients)
ACETAMINOPHEN (1214 patients)
METHOTREXATE (1001 patients)
FUROSEMIDE (863 patients)
ALLOPURINOL (848 patients)
EXJADE (832 patients)
OMEPRAZOLE (830 patients)
ZYPREXA (779 patients)
NORVASC (763 patients)
ARAVA (711 patients)
KETEK (703 patients)
ZOMETA (681 patients)
REMICADE (659 patients)
FOLIC ACID (655 patients)
FAMOTIDINE (613 patients)
LEVOTHYROXINE SODIUM (606 patients)
DIOVAN (600 patients)
PREDNISONE (597 patients)
LISINOPRIL (593 patients)
SEROQUEL (591 patients)
TEGRETOL (591 patients)
GLEEVEC (570 patients)
LANSOPRAZOLE (570 patients)
VOLTAREN (563 patients)
SIMVASTATIN (561 patients)
PREDONINE (552 patients)
COUMADIN (551 patients)
LORAZEPAM (545 patients)
NEXAVAR (543 patients)
ZOCOR (540 patients)
IBUPROFEN (539 patients)
ATENOLOL (537 patients)
NEXIUM (525 patients)
SYNTHROID (509 patients)
CRESTOR (507 patients)
LAMICTAL (504 patients)
ACCUTANE (496 patients)
POTASSIUM CHLORIDE (470 patients)
CYCLOPHOSPHAMIDE (468 patients)
LAMISIL (462 patients)
WARFARIN SODIUM (462 patients)
NEURONTIN (458 patients)
AMBIEN (434 patients)
AMLODIPINE (433 patients)
DIGOXIN (430 patients)
ACYCLOVIR (429 patients)
HYDROCHLOROTHIAZIDE (429 patients)
CLONAZEPAM (427 patients)
PAXIL (421 patients)
CYTARABINE (420 patients)
PLAVIX (416 patients)
ALDACTONE (412 patients)
FOSAMAX (410 patients)
VIOXX (408 patients)
DECADRON (406 patients)
OXYCONTIN (404 patients)
LOXONIN (403 patients)
MAGNESIUM OXIDE (403 patients)
BACTRIM (403 patients)
VANCOMYCIN (398 patients)
DEXAMETHASONE (396 patients)
METFORMIN HCL (394 patients)
MUCOSTA (382 patients)
FLUCONAZOLE (369 patients)
SPIRONOLACTONE (367 patients)
NEORAL (366 patients)
PROTONIX (366 patients)
XANAX (363 patients)
CYCLOSPORINE (363 patients)
RISPERDAL (358 patients)
STRATTERA (357 patients)
ATIVAN (356 patients)
ENBREL (355 patients)
ZETIA (355 patients)
MORPHINE (354 patients)
ALBUTEROL (354 patients)
ZOLOFT (352 patients)
LYRICA (346 patients)
LOVENOX (342 patients)
DEPAKENE (341 patients)
AVONEX (333 patients)
ZOFRAN (331 patients)
ZANTAC (325 patients)
CARBOPLATIN (322 patients)
MYLOTARG (320 patients)
AMARYL (320 patients)
VELCADE (317 patients)
AUGMENTIN '125' (316 patients)
LEVOFLOXACIN (306 patients)
PREDNISONE TAB (305 patients)
SOLU-MEDROL (304 patients)
RIBAVIRIN (303 patients)
CIPROFLOXACIN (299 patients)
LAMIVUDINE (298 patients)
CLOZARIL (291 patients)
SELBEX (289 patients)
VICODIN (288 patients)
PREVACID (281 patients)
RHEUMATREX (281 patients)
URSO 250 (280 patients)
LEXAPRO (277 patients)
DIFLUCAN (275 patients)
OXYCODONE HCL (275 patients)
INSULIN (274 patients)
CISPLATIN (272 patients)
FENTANYL (272 patients)
PEG-INTRON (267 patients)
SINGULAIR (265 patients)
ALLEGRA (261 patients)
PRILOSEC (261 patients)
CLARITHROMYCIN (261 patients)
VITAMIN D (261 patients)
TOPROL-XL (261 patients)
GASTER (260 patients)
MULTI-VITAMINS (260 patients)
LANTUS (258 patients)
CARBAMAZEPINE (257 patients)
MORPHINE SULFATE (255 patients)
REBETOL (253 patients)
ENALAPRIL MALEATE (252 patients)
CELEBREX (252 patients)
RAMIPRIL (252 patients)
AMLODIPINE BESYLATE (252 patients)
GABAPENTIN (251 patients)
ATORVASTATIN CALCIUM (250 patients)
FLUOROURACIL (247 patients)
ZYRTEC (243 patients)
REBIF (242 patients)
REVLIMID (242 patients)
IRESSA (241 patients)
HEPARIN (241 patients)
EFFEXOR (239 patients)
NORVIR (237 patients)
METOPROLOL TARTRATE (237 patients)
PANTOPRAZOLE SODIUM (236 patients)
DIAZEPAM (235 patients)
AMOXICILLIN (233 patients)
PROGRAF (231 patients)
METHYLPREDNISOLONE (230 patients)
PERCOCET (229 patients)
RANITIDINE (229 patients)
AVASTIN (226 patients)
ALPRAZOLAM (224 patients)
PEGASYS (218 patients)
PACLITAXEL (218 patients)
TYLENOL (216 patients)
MULTI-VITAMIN (215 patients)
KALETRA (214 patients)
TRAMADOL HCL (214 patients)
ACTOS (213 patients)
ADVAIR DISKUS 100/50 (212 patients)
KEPPRA (210 patients)
HUMIRA (209 patients)
TRUVADA (208 patients)
TRAZODONE HCL (207 patients)
TAKEPRON (206 patients)
PEPCID (206 patients)
ATARAX (206 patients)
VFEND (205 patients)
CALCIUM (205 patients)
ZOLPIDEM TARTRATE (204 patients)
METFORMIN (202 patients)
VALTREX (202 patients)
TYSABRI (198 patients)
PLATELETS (198 patients)
PURSENNID (197 patients)
BENADRYL (196 patients)
VALPROATE SODIUM (196 patients)
GASMOTIN (196 patients)
GLYBURIDE (195 patients)
PROZAC (195 patients)
KYTRIL (195 patients)
LEVAQUIN (194 patients)
MIRTAZAPINE (193 patients)
COMPAZINE (191 patients)
DEPAS (191 patients)
NITROGLYCERIN (190 patients)
ASCORBIC ACID (188 patients)
ACETYLSALICYLIC ACID SRT (186 patients)
GLUCOPHAGE (185 patients)
DICLOFENAC SODIUM (185 patients)
GEMZAR (184 patients)
TACROLIMUS (183 patients)
ICL670A ICL+DISTAB (182 patients)
VITAMIN E (181 patients)
EPIVIR (180 patients)
NIFEDIPINE (180 patients)
RITONAVIR (180 patients)
SORAFENIB (RAF KINASE INHIBITOR) (179 patients)
AMITRIPTYLINE HCL (178 patients)
ABILIFY (178 patients)
PARACETAMOL (177 patients)
VIREAD (176 patients)
BACLOFEN (176 patients)
ETOPOSIDE (176 patients)
DOXORUBICIN HCL (176 patients)
MEDROL (175 patients)
ZIDOVUDINE (175 patients)
PANTOPRAZOLE (174 patients)
CELEXA (173 patients)
VINCRISTINE (173 patients)
AREDIA (172 patients)
BISOPROLOL FUMARATE (172 patients)
ROCEPHIN (172 patients)
ACTONEL (171 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ASPARTATE AMINOTRANSFERASE INCREASED and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.